INTRODUCTION AND OBJECTIVES: Intermittent androgen deprivation therapy can only be appropriately evaluated in a randomized fashion. We present updated follow up results, to Sept 2016, from the SEUG 9901 Phase III study comparing the intermittent monotherapy with continuous combined androgen deprivation using an LHRH analogue and ciproterone acetate and associated components of quality of life.
METHODS: Patients with advanced prostatic cancer and M1 received cyproterone acetate (200 mg/day), administered for two weeks, and LhRh agonists (1 monthly depot injection)started after two weeks of Lead-in-therapy, and given every four weeks thereafter. After 3 months when the PSA is bellow 4 ng/ml, patients where randomised between continuous therapy LhRh plus CPA (200 mg/day) and intermittent therapy CPA (300 mg/day).
RESULTS: 1045 men with a median PSA of 15.9ng/ml were registered between October 1999 and September 2007. 24.5% of registered patients have a PSA less than 10ng/ml; 39.5% of registered patients have a PSA greater than 20ng/ml. 90.3% have a T3 tumour and 5.6% T4; only 14% have metastatic prostate cancer, 63% have Gleason Score 6-7 and 21% Gleason 8þ. 918 patients (aged 44-81, mean 72) have been randomized 462 to Intermittent therapy and 456 to Continuous. The median PSA at randomisation is 1.0 ng/ml ranging from 0.1 to 9. 49.2% of patients have a PSA less than 1 ng/ml at randomisation.
The maximum follow up is 15.6 years with a median of 5 Median survival is 6.5 years (95% CI 6.0, 6.9) and 535 patients have been followed up for at least five years, with 361 for at least 7 years and 195 for at least 10 years (22% of those randomized to intermittent therapy and 21% of those on continuous). Metastatic status, PSA at randomisation and age at randomization are all prognostic factors for survival. M1 patients have an increased risk of dying (HR¼1.67, 95% CI 1.30, 2.13) and there is a trend for an increasing hazard of death with increasing age so that men aged 75þ have a hazard ratio of 1.73 (95% CI 1.16, 2.57) compared to men aged under 60. Men whose PSA falls to between 2 and 4 have an increased hazard of dying relative to those whose PSA falls below 0.5 (HR¼1.88, 95% CI 1.53, 2.30). There was no evidence that T Stage (p¼0.76) or Gleason score (p¼0.09) are associated with an increased risk of death.
Adjusting for Age, PSA and metastatic status, patients on continuous therapy had an elevated hazard of death, HR¼ 1.13 (95% CI 0.97, 1.32), p ¼ 0.13. The hazard of a CVD death is HR¼1.22 (95% CI 0.96, 1.55, p ¼ 0.11), while for other metastatic disease it is HR ¼ 0.64(95% CI 0.35, 1.19, p ¼ 0.16). For Prostate cancer HR ¼ 1.08 (95% CI 0.82, 1.43, p ¼ 0.57), and for other causes of death it is HR ¼ 1.18 (95% CI 0.82, 1.70, p ¼ 0.36).
CONCLUSIONS: Follow up has been extended to a maximum of 15 years and 20% of patients are still in active follow up. We are much closer to the 658 deaths specified in the protocol and there is no evidence that an initial treatment with intermittent therapy is harmful to patients in that overall survival is poorer. If anything, survival is poorer on continuous therapy driven largely by elevated cardio vascular deaths. There is no difference in prostate cancer deaths, though those randomized to intermittent therapy have a greater hazard of a death due to a non-prostate cancer . 197, No. 4S, Supplement, Sunday, May 14, 2017 ascertained at least 180 days after prostate cancer diagnosis. We used 1:1 propensity scoreematched analysis ,multivariable-adjusted Cox proportional hazards models to investigate the association between ADT use and the risk of autoimmune diseases RESULTS: Of the 17,168 selected prostate cancer patients, 16,379 patients were met our inclusion and exclusion criteria, with 7,025 receiving ADT and 9,354 were no-ADT users. After 1:1 propensity score matching, there were 5,590 ADT users and 5,590 non-ADT users in the study cohort. During a mean follow-up period of 5.1 years, 457 patients were newly diagnosed with autoimmune diseases with 155 among ADT users and 302 among non-ADT users. Kaplan-Meier curves demonstrated a higher cumulative probability of remaining autoimmune diseases-free among ADT users (Figure 1) . Compared to non-ADT users, ADT group was statistically associated with a decreased risk of autoimmune diseases (adjusted hazard ratio (HR) 0.63, 95%CI 0.52-0.76) after Cox proportional hazards models. More specially, ADT users had a decreased risk of Graves' disease (aHR 0.46, 95%CI 0.23-0.91), psoriasis (aHR 0.53, 95%CI 0.29-0.97), type 1 diabetes (aHR 0.33, 95%CI 0.17-0.63), and uveitis (aHR 0.51, 95%CI 0.26-0.97) ( Table 1) .
CONCLUSIONS: The result of this study indicated that ADT use in patients with prostate cancer may decrease the risk of autoimmune diseases, especially in Graves' disease, psoriasis, type 1 diabetes, and uveitis. Further studies are warranted to further investigation to obtain a better understanding between ADT and autoimmune diseases. The literature suggests that statin treatment may influence outcomes for patients across cancers such as pancreatic and breast cancer. Although 30% of men age 40 use statins, little is known about the impact of statins on outcomes for patients treated for mCRPC, particularly the potential for variation in the effect of mCRPC oral treatments. This study examined the association between statin use, mCRPC oral treatments, and patient outcomes in a real-world setting.
Source of Funding
METHODS: A national health claims database was used to conduct a retrospective study of patients initiated on oral treatments for mCRPC (abiraterone acetate plus prednisone (ABI) or enzalutamide (ENZ)) from 2012-2015. Treatment cohorts and index date were defined based on first medication initiated (ABI/ENZ). Included patients had: 1 prostate cancer claim (ICD-9-CM 185.xx) from 6 months pre-to 30 days post-index date; 6 month pre-index and 3 months post-index health plan enrollment (retaining patients who died). Outcomes assessed included new central-nervous system conditions, bone, brain and visceral metastases, duration of treatment, and mortality. Descriptive analyses and Cox proportional hazards assessed the impact of statins and of ABI/ENZ; models adjusted for age, region, pre-index comorbidities, bone/brain/visceral metastases and docetaxel use.
RESULTS: Follow-up statin use was similar for the cohorts, with 40.82% of 1,095 ABI vs. 38.24% of 421 ENZ treated (P¼0.36) patients using statins. The proportion of days covered by statins were 63% (ABI) and 60% ENZ (P¼0.16). Follow-up statin use was associated with lower hazards of entering hospice (HR: 0.51, P¼0.005), discontinuing oral mCRPC treatments (HR: 0.62, P¼0.001), and mortality (HR: 0.54, P <0.001). ABI patients with statins had a lower hazard of CNS events (HR: 0.79; P¼0.031), while ENZ patient with statins had a higher hazard of CNS events (HR: 1.09; P¼0.026). ENZ patients with follow-up statins had a higher hazard of bone/brain metastases (HR: 1.24, P¼0.006).
CONCLUSIONS: For a population of real-world patients with mCRPC, statins were associated with improved outcomes and may lead to variability in the effect of oral treatments.
Source of Funding: Janssen Scientific Affairs, LLC
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INTRODUCTION AND OBJECTIVES: Recent studies suggested an inverse stage migration towards more aggressive pathological characteristics in high-risk prostate cancer. We evaluated whether patients with metastatic prostate cancer (mPCa) experienced changes in clinical patterns and oncological outcomes in the most recent years.
METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database, we identified 12,681 patients diagnosed with mPCa between 2004 and 2013. Only patients with complete clinical data were considered. After stratification according to the year of diagnosis, lowess smoother weighted functions were used to plot the prevalence of each metastatic stage, according to the sixth edition of American Joint Committee on Cancer [AJCC] Cancer Staging Manual (M1a, M1b, M1c), according to local T stage (T1, T2, T3þ) and according to biopsy Gleason score (6, 7, 8) . Similarly, overall mortality
